The USC Annenberg Center for Public Relations' annual Relevance Report is a collection of essays from professionals and academics that identify emerging issues, examine current strategies and forecast future trends. Contributions in the 2019 collection include thought pieces on healthcare technology, retailing, brands, inclusion and diversity, and the future of business communication.
Cincinnati Children’s Hospital Medical Center, seed investor CincyTech announced the formation and seed financing of Clarigent Health, a platform technology company leveraging artificial intelligence and natural language processing to give health care providers a new clinical decision support tool to address suicide, which in recent years has risen at alarming rates among teens.
The U.S. Department of Energy’s (DOE) Argonne National Laboratory has signed a Memorandum of Understanding (MOU) with mHUB, a Chicago-based innovation center dedicated to physical product development and manufacturing.
The lead battery is headed for a high-tech makeover that will make this sustainable mainstay product more appealing to the automotive industry and the power grid. Under the terms of a new agreement signed with the U.S. Department of Energy’s Argonne National Laboratory, 14 members of the Advanced Lead Acid Battery Consortium (ALABC) have joined forces with Electric Applications to grapple with some of their common challenges.
TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, are pleased to announce that they have agreed to pursue a strategic partnership around the commercial production of Actinium-225, a rare medical isotope that has the potential to serve as the basis of new ground-breaking cancer treatments.
B-Line Medical®, an industry leader in video-driven healthcare education and outcome improvement, is excited to celebrate International Healthcare Simulation Week with the Society for Simulation in Healthcare.
The DREAMS public-private partnership helps girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored and Safe women. DREAMS utilizes a multisector approach to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries.
University of California San Diego and Deerfield Management announce today the creation of Poseidon Innovation, LLC to advance disease-curing therapeutics. Through Deerfield’s $65-million commitment in Poseidon, UC San Diego investigators will have the funding and support to weather risky early-stage processes and expedite the drug-development cycle, allowing patients to receive treatment faster.
Researchers at ORNL have developed a new cybersecurity tool called Akatosh that automates the process of analyzing computer networks to detect malware. The tool collects historical information on host systems on the network to immediately show changes that transpired leading up to and during a cyber attack, which saves precious time and resources previously spent manually searching the network for changes.
Wolters Kluwer Health announced today it will begin electronic publishing of Evidence-Based Practice, the official journal of the Family Physicians Inquiries Network (FPIN). The monthly journal, which focuses on topics relevant to the daily practice of family medicine, will be curated in the Lippincott portfolio beginning in September 2018.
The University of Chicago Medicine and Humana Inc. have entered into a value-based agreement designed to offer a coordinated, patient-centered experience to help Humana Medicare Advantage members achieve their best health.
Dthera™ Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ.
MET is pleased to announce the forthcoming (August 20th) launch of their book Hand-Held Dynamometry: Guidelines for Daily Clinical Practice written by physical therapist Dr. Frank Aerts and occupational therapist Becky Alwood.
The University of Texas at El Paso will serve as the North American base of operations for Aconity3D, one of the world’s emerging technology leaders in the production of 3D printing equipment, under a new agreement announced by the two organizations this summer.
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
IMV, part of the Science and Medicine Group, the leading market research and business intelligence provider to the laboratory diagnostic industry, announced the category winners of the 2018 IMV ServiceTrak™ awards in clinical analyzers. Sysmex America, Inc. was recognized for:
•Best System Performance
•Best Customer Satisfaction
For decades, microbiologists have done their work by hand even as robotics and automation began to improve other laboratory processes. Until recently, the delicate techniques necessary to introduce mechanisms to microorganism study and analysis have been challenging for these divisions to automate. Now that's changing.
Ortho Clinical Diagnostics announced that, for the third year in a row, the Ortho Care™ service and support program was the highest-ranked original equipment manufacturer for overall service performance in the diagnostics industry.
Performance Motion Devices today announced that its ATLAS® digital amplifiers, featuring the highest power density in the industry, can now be used with third party microprocessors or field programmable gate arrays (FPGAs) via Serial Peripheral Interface (SPI) communications.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced that its VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS® HIV Combo test) received approval from the U.S. Food and Drug Administration for use on Ortho’s VITROS 3600 Immunodiagnostic System
Ortho Clinical Diagnostics received approval from the U.S. Food and Drug Administration for Ortho’s VITROS® Immunodiagnostic Products HBeAg Assay and the VITROS® Immunodiagnostic Products Anti-HBe Assay for use on the VITROS® 3600 Immunodiagnostic System and VITROS® 5600 Integrated System
Ortho Clinical Diagnostics announced that its VITROS® NEPHROCHECK® test received CE Mark. The VITROS® NEPHROCHECK® test is the first fully automated risk assessment tool for predicting Acute Kidney Injury (AKI), a serious and potentially fatal condition affecting hospital patients worldwide
Ortho Clinical Diagnostics’ VITROS® XT 7600 Integrated System received CE Mark. By combining Ortho’s proprietary dry slide technology with sophisticated digital imaging and the potential to perform two separate lab tests simultaneously, Ortho introduces digital chemistry to clinical lab management
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced an international distribution and co-promotion agreement with Thermo Fisher Scientific to provide 14 assays used to monitor therapeutic drugs, immunosuppressive drugs and drugs of abuse.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced it will officially unveil the VITROS® XT 7600 Integrated System, now available in numerous countries that accept CE Mark, at the 2018 AACC Annual Scientific Meeting & Clinical Lab Expo
Sysmex, one of the fastest growing providers of diagnostic hardware and software in the U.S., celebrates its 50th anniversary in booth number 1231 at this year’s annual meeting of the American Association for Clinical Chemistry (AACC). The company is also sharing its plans to equip the clinical laboratory of the future with innovative solutions in flow cytometry, urinalysis and hematology.
Responding to customer requirements to handle increased volumes in decentralized clinical testing, MedTest Dx today announced the introduction of its BA-800M Clinical Analyzer for general chemistry with a full line of reagents and the launch of its BC-5390 5-Part Differential Hematology Analyzer at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting.
Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G B•R•A•H•M•S PCT Assay for testing on its LUMIPULSE® G1200 immunoassay platform.
Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the Company”) announced today that it has entered into an agreement with US-based Janssen Pharmaceuticals, Inc. (hereinafter “Janssen”) to develop and commercialize an AMYLOID β 42/40 RATIO assay.
MedTest Holdings, the solution provider of choice offering integrated products and services for decentralized clinical diagnostic testing, today announced the debut of its new corporate name—MedTest Dx—at the upcoming 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting.
Brandwidth Solutions, LLC, a full-service marketing agency addressing science-based businesses, has been recognized as Best Specialist Life Science Marketing Agency 2018-Pennsylvania by AI Global Media.
SCIEX, a global leader in life science analytical technologies, advanced the accessibility of mass spectrometry in the clinical setting with new product introductions at AACC 2018. Today, SCIEX announced the launch of the new Topaz™ Prep Station, an automated sample preparation workstation that is ideal for labs managing high daily sample volumes, as well as the new automated Vitamin D 200A Assay Kit.
Hahn-Schickard enables complex clinical pictures to be diagnosed quickly and reliably directly at the point of care. The latest device generation allows the amplification of RNA and DNA by means of fast PCR in 20 - 25 minutes. This makes it possible, for example, to analyze a real patient sample fully automatically in 30 minutes. The device can also be used in the field of food analysis or environmental analysis.
NAMSA®, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory testing, clinical research and regulatory consulting services, announced today the launch of its in vitro diagnostic (IVD) development business to provide global manufacturers a proven resource for expedited commercialization outcomes delivered via NAMSA’s “Uniquely IVD” regulatory, quality and clinical research services.
Neoteryx LLC today announced research recently published in the official peer-reviewed scientific journal of the European Federation of Clinical Chemistry and Laboratory Medicine, Clinical Chemistry and Laboratory Medicine. The research found that analysis of samples extracted from the company’s VAMS™ technology showed almost perfect agreement with results obtained from venous blood samples for HbA1c levels on a Tosoh G8 analyzer. The investigator-initiated clinical research study took place from June 2017 to January 2018 at Ghent University Hospital in Belgium. The study included 100 patients and was approved by the school’s Ethics Committee.
Neoteryx LLC, announced today the expansion of its patent-pending Mitra® Microsampling portfolio to now include a 30 µL tip size. The Mitra microsampling device which comes in a 10 µL, 20 µL and now 30 µL holds and transports a precise volume of blood typically collected from a finger prick.
Today, Neoteryx LLC, announced that it will supply its Volumetric Absorptive Microsampling (VAMS™) technology, in the form of the Mitra® microsampling device, to Alcala Labs of San Diego for a more efficacious, streamlined approach to monitor patients in recovery centers throughout the United States. By incorporating VAMS specimen collection and transportation technology into its CleanAssure™ clinical convenience kits and testing menu, Alcala Labs is the first to commercialize an offering to addiction recovery centers that analyzes a volumetrically accurate dried blood microsample collected from a simple finger prick to test for alcohol and opioids.
Magnefy offer an additional performance-driven solid phase for magnetic particle-based assays and isolations, including SPRI-based* total DNA isolation. (*Solid phase reversible immobilization, which features the isolation of high-purity nucleic acid in the presence of NaCl and PEG.)